Citius Oncology Inc (NASDAQ:CTOR) does about 127.50K shares in volume on a normal day but saw 4310903 shares change hands in the recent trading day. The company now has a market cap of 71.10M USD. Its current market price is $1.02, marking an increase of 10.98% compared to the previous close of $0.92. The 52 week high reached by this stock is $49.00 whilst the lowest price level in 52 weeks is $0.85.
Citius Oncology Inc (CTOR) has a 20-day trading average at $1.0718 and the current price is -97.92% off the 52-week high compared with 20.00% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.1647 and its 200-day simple moving average is $7.7319. If we look at the stock’s price movements over the week, volatility stands at 19.16%, which decreases to 14.17% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 44.78 to suggest the stock is neutral.
The consensus objective for the share price is $3.00, suggesting that the stock has a potential upside of 66.0% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 27, 2024 when Maxim Group initiated the stock to “Buy” and issued a price target of $3.
The current price level is -4.84%, -12.43%, and -86.81% away from its SMA20, SMA50, and SMA200 respectively, with the CTOR price moving above the 50-day SMA on current market day. Citius Oncology Inc (CTOR) stock is up 19.70% over the week and -13.92% over the past month. Its price is -90.68% year-to-date and -90.19% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 66.0 percent from here.
Outstanding shares total 2.34M with insiders holding 95.88% of the shares and institutional holders owning 0.73% of the company’s common stock. The company has a return on investment of 4.19% and return on equity of 3.35%. The price to earnings ratio (P/E ratio) amounts to 4.17. The beta has a value of -0.21.
